B*44 restricted peptides for use in immunotherapy against cancers and related methods

Patent metadata

Field	Value
Publication number	US-11208448-B2
Application number	US-202016916443-A
Country	US
Kind code	B2
Filing date	Jun 30, 2020
Priority date	Sep 17, 2018
Publication date	Dec 28, 2021
Grant date	Dec 28, 2021

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

First claim

The invention claimed is:

1. A method of treating a patient who has cancer, wherein the cancer comprises cancer cells that overexpress TRPS1 polypeptide and present at their surface in a complex with an MHC class I molecule a peptide consisting of the amino acid sequence of SEQ ID NO: 332, comprising administering to said patient a population of autologous activated cytotoxic T cells that bind the peptide consisting of the amino acid sequence of SEQ ID NO: 332 in a complex with an MHC class I molecule, and thereby target and kill the cancer cells,
wherein said cancer is melanoma or non-Hodgkin lymphoma.

2. The method of claim 1 , wherein the autologous activated cytotoxic T cells are produced by contacting T cells obtained from the patient with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cells obtained from the patient.

3. The method of claim 1 , further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

4. The method of claim 1 , wherein the cancer is the melanoma.

5. The method of claim 1 , wherein the cancer is the non-Hodgkin lymphoma.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Song Colette
• Schuster Heiko
• Kowalewski Daniel Johannes
• Schoor Oliver
• Fritsche Jens
• Weinschenk Toni
• Singh Harpreet

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• C12N5/0636

  T lymphocytes · CPC title

• A61K39/0011

  Cancer antigens · CPC title

• A61K35/17

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title